VX-745

Research use only, not for human use.

A potent and selective p38α kinase inhibitor with IC50 of 9 nM; shows 20-fold selectivity for p38α over p38β (Ki=220 nM) and no significant inhibition for MAP kinases (with the exception of MKK6).

A potent and selective p38α kinase inhibitor with IC50 of 9 nM; shows 20-fold selectivity for p38α over p38β (Ki=220 nM) and no significant inhibition for MAP kinases (with the exception of MKK6); exhibits inhibition of PBMC IL-1β and TNFα IC50 of 45 and 51 nM, respectively; possesses favorable PK profile, and demonstrates good in vivo activity in models of inflammation.Alzheimer's Disease Phase 2 Clinical.

——

——

VX 745 | VX745 | Neflamapimod

MAPK/ERK Signaling

p38 MAPK

p38α|p38β

Neurological Disease

Alzheimer Disease

209410-46-8

436.2621

C19H9Cl2F2N3OS

>98% (HPLC)

DMSO: 13.08 mg/mL (Need ultrasonic)

O=C1C(C2=C(Cl)C=CC=C2Cl)=C3C=CC(SC4=CC=C(F)C=C4F)=NN3C=N1

6H-Pyrimido[1,6-b]pyridazin-6-one, 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)thio]-

(-20℃)

With Ice Pack

≥ 2 years